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Abstract
Genetic variation within Toxoplasma gondii can have both clinical and epidemiological significance, while the genotypes
circulating in many parts of the world, including the Nordic country Denmark, are still unknown. We genetically characterized
T. gondii strains that had been detected in human clinical samples in Denmark in 2011–2016. Samples that had tested positive for
T. gondii DNA and had a quantification cycle value <33 were included in this study and subjected to direct genetic character-
ization of T. gondii based on length-polymorphism of 15 microsatellite markers. A total of 23 DNA samples from 22 individual
patients were analyzed. The results were consistent with genotype II with 15/15 markers amplified from seven samples from the
central nervous system (CNS) including two samples from one patient, four ocular samples, and one unspecified sample; with
genotype III with 15/15 markers amplified from two ocular samples; with genotype Africa 1 with 15/15 markers amplified from
one amniotic fluid sample and from one CNS-sample; with atypical genotype with 15/15 markers amplified from one CNS-
sample and with 11/15 markers amplified from one CNS-sample; and with HG12-like genotype with 9/15 markers amplified
from one CNS-sample. Genotype II, which is endemic in Europe, was predominant, but more than a third of the successfully
genotyped strains were non-type-II. The possibility that clinical toxoplasmosis is caused by a strain that is not considered
endemic to the region is definitely not negligible.
Introduction
Many aspects, including characteristics of both the host and
the parasite, affect the outcome of infection with Toxoplasma
gondii [1]. Genotype II strains of T. gondii appear to predom-
inate in Europe: in France, more than 90% of strains have been
genotype II strains [2]. Genotype II strains are nonvirulent for
most strains of laboratory mice [1] but able to cause clinical
disease and deaths in humans [3–6] as well as in animal hosts
[7–13]. Genotype III has been described as the second most
common genotype in Europe [4]. Strains that are atypical from
the European point of view and mostly found in South
America have appeared more virulent [14–19], and introduc-
tion of such highly virulent T. gondii strains to Europe has
been considered an emerging biological risk [20].
The Laboratory of Parasitology of Statens Serum Institut
(SSI) is located in Copenhagen, Denmark, and functions as
the national T. gondii reference laboratory offering a range of
indirect and direct methods to diagnose T. gondii infections.
During 2003–2016, the annual mean number of human clini-
cal samples that were tested for presence of T. gondii DNA
was 79 [21]. Themajority of the samples were from the central
nervous system (CNS) or ocular samples, and 8.6% of them
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tested positive. However, the genotypes causing clinical dis-
ease—based on the submitted samples including a wide vari-
ety of manifestations from lymphadenopathy to congenital
toxoplasmosis [21, 22]—have been unknown. In 2011, a
small pilot study applying T. gondii genotyping to six clinical
samples found genotype II strain in two samples and genotype
Africa 1 strain in one sample (H. V. Nielsen and D. Ajzenberg,
unpublished data). In this study, we genetically characterized




We investigated archived surplus of DNA samples that had
been extracted from clinical samples. The study was retro-
spective and did not involve any contact with the patients.
The samples and data were coded and handled confidentially,
and are presented so that the individual patients cannot be
identified.
Inclusion criteria
Our sampling frame was DNA samples routinely extracted
from various human clinical samples submitted to the
Danish national T. gondii reference laboratory, SSI, for diag-
nostic real-time PCR for detecting T. gondii DNA. To our
knowledge, all or most PCR diagnostics for suspected toxo-
plasmosis is referred to our laboratory, i.e. the sampling frame
was of nationwide scope. The diagnostic real-time PCR
targeted the repetitive 529 bp DNA fragment [23]. We includ-
ed DNA samples that had tested positive for T. gondiiDNA in
2011–2016 with a quantification cycle (Cq) value <33 and that
were available as surplus material for this study.
Direct genetic characterization of T. gondii
The genetic characterization method that we used is based on
length-polymorphism of 15 microsatellite markers [24]. Each
run included DNA of the ME49 strain that had been extracted
from brain tissue of a laboratory mouse as a positive control
and reference to ensure that the expected fragment sizes were
retrieved. Sample ID 2 was diluted 1:4 and sample ID 14 was
diluted 3:2 due to limited volume available, other samples
were subjected to the analysis directly. The analysis was per-
formed blinded.
Distance analysis (tree)
To evaluate the position of strains genotyped with all 15
markers amplified in the present study in relation to a selection
of reference strains and strains isolated worldwide, a
neighbor-joining analysis of the 15 microsatellite markers
was repeated for 1,000 bootstrap replicates and displayed as
an unrooted tree drawn using MEGA version 6. The strains
included in the tree were selected to represent the worldwide
diversity of T. gondii genotypes currently known, as well as to
increase the visible diversity of the haplogroups to which
strains from the present study belonged. The results of genetic
characterization for the 70 strains used in the distance analysis
are shown in Online Resource 1.
Statistical analyses
We used the open-source software OpenEpi [25] to calculate
95% confidence intervals (95% CI, Mid-P exact) for the pro-
portions and for two-by-two table comparisons (two-tailed P-
value, Mid-P exact). Further statistical analyses were per-
formed with Stata 13.1 (StataCorp, College Station, TX,
USA). P-values (P-values, two-tailed, Mid-P exact, from
two-by-two table comparisons; P-values as provided by
Stata, P > |z| and Prob > chi2) < 0.05 were considered statisti-
cally significant.
For the statistical analyses, we dichotomized the successful
genotyping results into type-II or -III and non-type-II nor -III
(outcome) and included only one result per patient. We con-
sidered amplification of ≥5 of the eight genotyping markers
(TUB2, W35, TgM-A, B18, B17, M33, IV.1, XI.1) as successful
genotyping. The variables evaluated were dichotomous: age
group of the patient (< 55 years or ≥55 years), gender of the
patient (female or male), whether the patient was reported to
be immunocompromised, whether the sample was from the
CNS or an ocular sample, and sampling period (2011–2013 or
2014–2016). Each variable was first evaluated using a two-
by-two table and univariable regression analysis. Building
multivariable regression models was attempted by including
all variables followed by backward elimination of those with
P-values >0.05 that did not act as confounders. The predictive
ability of the models with significant variable(s) was evaluated
as the area under the receiver operating characteristic (ROC)
curve. Maximum area under the ROC curve would be 1.0,
while an area of 0.5 would indicate no predictive ability at all.
Data availability All data generated and analyzed during this
study are included in this published article and its supplemen-
tary information files.
Results
A total of 544 samples were received at the laboratory for the
real-time PCR for T. gondii DNA in 2011–2016. Of them, 51
(9.4%, 95% CI 7.1–12.1) had tested positive. This proportion
testing positive was not statistically different from the
580 Eur J Clin Microbiol Infect Dis (2018) 37:579–586
proportion testing positive in 2003–2016 (8.6%; 95% CI, 7.1–
10.4; P-value 0.6082) [21]. The Cq-values of the positive
samples ranged from 14.62 to 40.89 (mean, 30.19; median,
31.78); few with a high Cq-value had a comment ‘doubtful’.
The Cq-values were unavailable for four positive samples.
Altogether, 27 samples had Cq-value <33. Four of these sam-
ples were not available as surplus for this study, thus the final
sample size became 23 samples, which was 4.2% of all sam-
ples received at the laboratory for the real-time PCR for
T. gondii DNA during 2011–2016.
The 23 DNA samples included in this study were from 22
individual patients. The Cq-values ranged from 15.18 to 32.33
(mean, 25.66; median, 25.55). The age of the patients ranged
from 24 years to 81 years (mean, 59.8 years; median,
61.5 years), and 12 (55%) of them were female and 10
(45%) were male. The mean age was 59.9 years among the
females and 59.7 years among the males; the median age was
63.5 years among the females and 60.5 years among the
males. All patients except one had a Danish civil registration
number. Twelve samples, including two samples from one
patient, were from 2011 to 2013, and 11 samples were from
2014 to 2016. Eleven of the samples, including two samples
from one patient, were CNS-samples, nine of the samples
were ocular samples, and one was amniotic fluid. The sample
material was unspecified for two samples. The CNS-samples
were from individuals with a mean age of 58.8 years, and the
ocular samples were from individuals with a mean age of
66.1 years. Information about immunostatus was not consis-
tently provided. Six (27%) of the patients were reportedly
immunocompromised; the samples from them were CNS-
samples. By contrast, all ocular samples and the amniotic fluid
sample we re f rom ind iv idua l s no t r epo r t ed as
immunocompromised.
The results of genetic characterization of T. gondii
from the 23 clinical samples as well as of the reference
and control strain ME49 are shown in Table 1. All 15/15
markers [24] were amplified from 17 samples (Table 1,
Fig. 1). No results were obtained from one ocular sample
and one unspecified sample. The samples yielding no re-
sults were both from the more recent sampling period
2014–2016; the mean number of markers amplified was
13 from samples from 2011 to 2013 and 11 from samples
from 2014 to 2016. Genotyping was successful (≥ 5 of the
8 genotyping markers amplified) from altogether 19 sam-
ples, including two samples from one patient: from all 17
samples with Cq-value <30 (including the two samples
that had to be diluted) and from two out of six samples
with Cq-value ≥30 and <33 (Table 1). Altogether, nine
markers were amplified from the sample diluted 1:4 and
all 15 markers from the sample diluted 3:2. There was no
evidence of mixed infections with several genotypes. Two
of the results were identical and those two samples were
from the same patient.
Genotype II was the most common genotype identified: of
the 18 patients with the parasite strain successfully genotyped,
genotype II strain was found in 11 (61%). Results consistent
with genotype II, with 15/15 markers amplified, were obtain-
ed from seven CNS-samples (including two samples from one
patient), four ocular samples, and one unspecified sample. In
addition, results suggestive of genotype II, with fewer markers
amplified, were obtained from two ocular samples. Results
consistent with genotype III, with 15/15 markers amplified,
were obtained from two ocular samples. These two genotype
III strains were very close to each other, differing by one
dinucleotide on marker N61.
Results consistent with genotype Africa 1, with 15/15
markers amplified, were obtained from one CNS-sample and
from one amniotic fluid sample. Results revealing atypical
genotypes, with 15/15 and 11/15 markers amplified, were ob-
tained from two CNS-samples. Results very close to those
from strains identified as HG12 but with an unusual type I
allele on marker TUB2, with 9/15 markers amplified, were
obtained from one CNS-sample.
The statistical analysis included successful genotyping
results from 18 patients: 13 (72%) type-II or -III, and 5
(28%) non-type-II nor -III results (Table 2). The three
patients who were <50 years old all had a non-type-II
nor -III result, and four out of five patients who were
<55 years old had a non-type-II nor -III result (two-by-
two table comparison, P-value 0.0078, Table 2). Based on
the results of logistic regression analyses, estimated using
data from the 18 patients, the only significant risk factor
for having non-type-II nor -III strain was younger age.
Based on the results of the univariable logistic regression
model, patients who were <55 years old had 48 (95% CI,
2.4–958.2; P-value 0.011) times higher odds to have non-
type-II nor -III strain than did patients who were ≥55 years
of age. The test of the overall model (Prob > chi2) was
0.0024, indicating the model was statistically significant.
The area under the ROC curve was 0.86, suggesting the
model would have good predictive power.
Discussion
The results of this study offer support for the predominance
of T. gondii genotype II strains in Europe [2, 5, 6]. However,
the results also highlight that genotype II strains are not the
only ones detected in clinical samples in this region: in this
study, almost 40% of the successfully genotyped strains
were non-type-II. Finding two genotype III strains is not
the most demonstrative, as strains of genotype III have been
found in Europe, as the second most common genotype [4],
as well as on other continents [26–29]. In this study using
clinical samples from Denmark, Africa 1 genotype was as
common as genotype III, and one strain of Africa 1
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genotype was also found in the pilot study. We also found
one strain of a HG12-like genotype, which shared similari-
ties to HG12 strains that represent the fourth clonal lineage
in North America [30]. One atypical genotype identified
with 15/15 markers amplified appeared quite far from
known genotypes and related to both Caribbean and
African strains (Fig. 1). All but one of the patients included
in this study had a Danish civil registration number, which
tells that they were registered in the national register on the
grounds of birth, due to immigration and stay of over
3 months, or for processing of taxes or pension. Where the
strains that we characterized in this study had been acquired
remains unknown. Nevertheless, it should be also noted that
naming genotypes based on geographical region may be
misleading, particularly as the global map of characterized
strains still has large areas with no data [2]. Our understand-
ing of the genetic variation within T. gondii by geographical
location is far from complete.
Four out of five patients who were <55 years old had a non-
type-II nor -III result (Table 2). This suggests that younger
generations seen by the Danish health care system could have
been exposed to a wider variety of strains, perhaps due to
different risk profile or more diverse background. The mean
age among the patients included in this study was 59.8 years,
and it is noteworthy that the ocular samples were from indi-
viduals with a mean age of 66.1 years. This was higher than
the mean age of 53.3 years among 20 patients with ocular
toxoplasmosis in a study from France [5] and the mean age
of 56.0 years among four patients with ocular toxoplasmosis
in a study from Germany [6]. These observations suggest that
Table 1 Genetic characterization of Toxoplasma gondii from 23 clinical samples from Denmark
Sample ID Cq-value Microsatellite markers Genotype
a
TUB2* W35* TgM-A* B18* B17* M33* IV.1* XI.1* M48 M102 N60 N82 AA N61 N83
1 25.55 289 242 207 158 336 169 274 356 235 174 145 115 287 95 310 II 15/15
2 29.17 291 NA 211 160 336 169 274 362 NA NA 142 NA NA 93 NA close to HG12
9/15
3 31.42 291 NA 205 160 336 NA 274 NA NA 166 147 111 271 87 306 Atypical 11/15
4 15.18 289 242 207 158 336 169 274 356 229 176 142 111 259 93 310 II 15/15
5 27.83 289 242 207 158 336 169 274 356 213 174 140 111 267 95 312 II 15/15
6 32.33 289 NA NA 158 NA 169 NA NA 216 NA NA NA NA 91 308 (II 6/15)
7 21.42 289 242 207 158 336 169 274 356 211 176 140 109 273 87 312 II 15/15
8 19.19 291 248 205 160 342 165 274 354 225 166 147 111 275 89 306 Africa 1 15/15
9 24.77 289 242 207 158 336 169 274 356 227 172 138 111 279 85 308 II 15/15b
10 23.60 289 242 207 158 336 169 274 356 227 172 138 111 279 85 308 II 15/15b
11 23.40 289 242 207 158 336 169 274 356 229 176 142 111 261 97 310 II 15/15
12 24.73 289 242 207 158 336 169 274 356 215 178 140 111 269 95 312 II 15/15
13 28.39 289 242 205 160 336 165 278 356 213 190 147 111 267 87 312 III 15/15
14 16.91 289 242 207 158 336 169 274 356 233 174 142 111 267 87 310 II 15/15
15 32.02 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA (NA)
16 24.03 289 242 207 158 336 169 274 356 211 176 271 113 271 93 308 II 15/15
17 31.13 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA (NA)
18 26.88 291 248 205 160 342 165 274 354 229 166 147 111 271 89 306 Africa 1 15/15
19 31.95 289 242 207 158 336 169 274 356 249 178 149 111 259 99 314 II 15/15
20 21.92 291 242 205 162 336 165 274 356 227 176 147 111 275 89 304 Atypical 15/15
21 18.76 289 242 205 160 336 165 278 356 213 190 147 111 267 89 312 III 15/15
22 30.78 NA NA 207 NA NA 169 NA NA NA 178 NA NA NA NA NA (II 3/15)
23 28.93 289 242 207 158 336 169 274 356 231 174 142 111 263 89 314 II 15/15
ME49c 289 242 207 158 336 169 274 356 215 174 142 111 265 91 310 II 15/15
Cq-value quantification cycle value, NA not amplified
Sample ID 2 was diluted 1:4 and sample ID 14 was diluted 3:2, other samples were subjected to the analysis directly
*Genotyping marker
a Genotype in parentheses if <5 of the 8 genotyping markers amplified
b Identical results; the two samples were from the same patient
c Reference strain
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clinical toxoplasmosis, and in particular ocular toxoplasmosis,
may be of particular and perhaps underemphasized relevance
for individuals who are over 50 years of age. The observation
that all ocular samples included in our study were from adult
individuals who were not reported as immunocompromised is
suggestive of acquired ocular toxoplasmosis. All samples
from reportedly immunocompromised individuals were
CNS-samples, indicating that T. gondii remains a relevant op-
portunistic threat [31].
The multilocus genetic characterization method [24] that
we used in this study allowed discrimination between
T. gondii strains at two levels: genotyping and fingerprinting,
i.e., insight into genetic variation also beyond the level of
genotyping. The genetic characterization was direct, i.e. with-
out preceding bioassay or cell culture step that could introduce
selection. We detected no mixed infections with more than
one strain. The two samples from one patient were correctly
identified as identical (Table 1). None of the other results were
Fig. 1 Neighbor-joining clustering of Toxoplasma gondii strains, based
on 15 microsatellite markers: black triangles are 17 strains with 15/15
markers amplified from clinical samples from Denmark; red, green, and
dark blue squares are reference strains of genotype I, genotype II, and
genotype III, respectively
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identical with each other, indicating that the infections were
from different, separate point sources.
The majority of the results were full results, with 15/15
markers amplified, illustrating that the method is suitable for
direct use on clinical samples, including clinical samples that
have been archived frozen. The DNA samples had been stored
frozen, some of them for years, which may have caused DNA
degradation but was not expected nor observed to have a ma-
jor effect on the results [32]. All samples with Cq-value <30
were successfully genotyped, whereas the success rate was
33% from samples with Cq-value ≥30 and <33 (Table 1). At
least in the setting at SSI, clinical samples that are positive for
T. gondiiDNAwith Cq-value <30 can be encouraged for direct
genotyping using this method. As this cut-off is close to the
mean and median of Cq-values of all samples that were posi-
tive for T. gondiiDNA, this would mean that about half of the
positive samples could be genotyped.
The current routine T. gondii diagnostics are done only to
the species level. Routinely characterizing the T. gondii strains
that are detected would yield baseline data that could prove
useful for detecting outbreaks, for source attribution, and for
preparedness to identify strains that are imported or newly
emerging to a region, or that might warrant different clinical
management. The results of this study highlight that clinical
toxoplasmosis can be caused by a genotype that is not consid-
ered endemic to the region.
The results of this study add to the knowledge on mo-
lecular and clinical epidemiology of T. gondii, although
with major limitations. Our results fill a geographical gap
and contribute to the current knowledge on global genetic
variation within T. gondii, but the sample is a referral-
biased tip of the iceberg of clinical T. gondii infections
in humans, likely a dead-end host species from the para-
site point of view. Based on the results of this study, we
cannot conclude which of the strains could be local; the
infections were diagnosed in Denmark but their origins
and sources remain unknown. It is possible that the
Africa 1 genotype strains were acquired in Africa, or that
the HG12-like genotype was acquired in North America.
However, it is also possible that they were acquired in
Denmark, which thus far has no genotype named after
it. The important point is that regardless of the origin of
the strains characterized in our study, they were causing
clinical disease and they were diagnosed in Denmark.
Epidemiology of T. gondii has a global scale, which is
crucial to take into account when addressing the disease
burden of toxoplasmosis [22, 33–37]. Because T. gondii
infection can be acquired at any point of the human
lifespan and clinical toxoplasmosis can be due to primary
or reactivated infection, the source and origin of the in-
fection often remain unknown. Region of origin or longer
stay may be of epidemiological relevance, but people
travel, move, and migrate. Moreover, foodborne infec-
tions may be acquired from imported food items. For ex-
ample, atypical T. gondii genotypes have been imported to
Europe in horse meat [19, 38]. Studies on local animal
hosts that likely acquire T. gondii infections from local
sources and that might serve as infection source for other
Table 2 The successfully genotyped Toxoplasma gondii strains from human clinical samples from 18 patients in Denmark, 2011–2016, categorized as
type-II or -III strains and non-type-II nor -III strains, shown by gender, age, reported immunostatus, sample material, and sampling period




Proportion non-type-II nor -III
% non-type-II nor -III 95% confidence interval P-value
Female 10 7 3 30 8–62 0.8431
Male 8 6 2 25 4–61
< 55 years old 5 1 4 80 33–99 0.0078*
≥ 55 years old 13 12 1 8 0.4–32
Not reported as
immunocompromised
12 9 3 25 7–54 0.7367
Immunocompromised 6 4 2 33 6–74
Ocular samplea 6 6 0 0 0–39 0.1154
Sample from the central
nervous systema
10 6 4 40 14–71
Sample from 2011 to 2013 10 7 3 30 8–62 0.8431
Sample from 2014 to 2016 8 6 2 25 4–61
Total 18 13 5 28 11–51
95% confidence interval, Mid-P exact
P-value, from two-by-two table comparison, two-tailed, Mid-P exact
* Statistically significant difference
a Other sample materials not shown
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hosts would provide the needed baseline data on locally
circulating strains.
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